dismiss

Come visit us at Booth 901 at AHRMM in Washington, DC
Mark your calendars! On August 2nd is our upcoming LIVE Clean Sweep Auction

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Business Affairs Homepage

GE Healthcare, Jefferson Health partner for $1 billion in efficiencies Eight-year deal will put over 100 GE staffers into 13 network hospitals

Higher upfront hospital inpatient spending reduces Medicare deaths and overall costs Figuring out what constitutes wasteful spending in health care

GE Healthcare acquires consulting firm Novia Strategies Company helped hospitals save hundreds of millions of dollars

Philips to enhance therapeutic offerings via dual acquisitions Innovating interventional procedures with Spectranetics and CardioProlific

Konica Minolta to acquire Ambry Genetics in $1 billion deal Will be 'first in a series' of precision medicine acquisitions

Commission alleges Canon's Toshiba Medical acquisition breached EU rules Fine could hit $2.9 billion

New research finds physician-hospital consolidation raises prices Horizontal and vertical integration are at play

Hologic takes FujiFilm to court over patent infringement The suit alleges that five patents in total are infringed upon

Cardiac remote monitoring firms to pay $13 million in fraud resolution Accused of billing Medicare for more costly cardiac monitoring than was needed

Survey finds most physicians view MACRA requirements as 'very burdensome' AMA offers resources to help

Absorb dissolvable stent shows higher cardio risk in some cases, FDA warns

by Thomas Dworetzky , Contributing Reporter
New concerns about the Absorb bioresorbable scaffold stent have come to light in two-year results of the ABSORB III trial, researchers reported at a clinical trials session at the American College of Cardiology’s 66th Annual Scientific Session, March 18.

“Patients receiving Absorb BVS faced an overall elevated risk of adverse outcomes at two years compared with patients receiving metal stents, a difference that appears to be attributable to the stent being placed in vessels that were smaller than recommended,” Absorb-maker Abbott said in a statement.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



The FDA has sent a letter about the issue to cardiologists and health care providers. The agency stated to those treating patients with the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) that there is “an increased rate of major adverse cardiac events observed in patients receiving the BVS, when compared to patients treated with the approved, metallic XIENCE drug-eluting stent.”

It specified that the findings showed “an 11 percent rate of major adverse cardiac events (e.g., cardiac death, heart attack, or the need for an additional procedure to reopen the treated heart vessel) in patients treated with the BVS at two years, compared with 7.9 percent in patients treated with the already-approved Abbott Vascular's metallic Xience drug-eluting stent,” noting, in addition, that the review also found “a 1.9 percent rate of developing blood clots within the BVS versus 0.8 percent within the Xience stent at 2 years.”

The FDA's guidelines advised “avoiding its use in small vessels.”

Cleveland Clinic cardiologist and the study's lead author Dr. Stephen Ellis called small-vessel avoidance a “key take-home” in the Abbott statement, adding that, "this isn't necessarily surprising, because the Absorb BVS is considerably larger than the Xience stent, but it would have been preferable to have more consistency with regard to the vessel sizing and utilization of the device in the study."

One-year results had shown absorbable stents were “non-inferior” compared with metal ones “as measured by a composite of cardiac death, target lesion heart attack and ischemia-driven target lesion revascularization.”

This changed between year one and two, however, as the latest report showed, according to Abbott. These new results demonstrated “that at the end of year two, patients receiving Absorb BVS showed a significantly higher risk of target lesion failure,” although there were some “inconsistencies with regard to adherence to study protocols and the procedural techniques used to place the device” that may have led to some of the adverse outcomes.
  Pages: 1 - 2 >>

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED